Best-in-class treatments in use today
For ovarian cancer, the most effective treatments are often a combination of surgery, chemotherapy, and targeted therapy. Surgery is typically the first step, where a doctor removes the tumor and as much of the affected tissue as possible. Chemotherapy is then used to kill any remaining cancer cells. This is usually a combination of drugs that target rapidly dividing cells, such as carboplatin and paclitaxel.
Targeted therapy is a newer approach that uses drugs to specifically target the genetic mutations that drive ovarian cancer. For example, bevacizumab is a drug that targets a protein called vascular endothelial growth factor (VEGF), which helps tumors grow new blood vessels. Bevacizumab is used to treat advanced ovarian cancer, particularly in patients with a specific genetic mutation called high-grade serous ovarian cancer.
Another important treatment is olaparib, a PARP inhibitor that targets a different genetic mutation. PARP inhibitors are used to treat ovarian cancer that has a specific genetic mutation, known as BRCA1 or BRCA2. These mutations make it harder for cells to repair DNA damage, and PARP inhibitors take advantage of this weakness.
What researchers are actively studying
Researchers are actively studying a range of new treatments for ovarian cancer, including new combinations of existing drugs and new targeted therapies. One area of focus is on improving the effectiveness of chemotherapy by combining it with other treatments, such as immunotherapy or targeted therapy. For example, researchers are studying the combination of carboplatin and paclitaxel with the immunotherapy drug pembrolizumab.
Another area of focus is on developing new targeted therapies that can specifically target the genetic mutations that drive ovarian cancer. For example, researchers are studying a new drug called niraparib, which is a PARP inhibitor that targets a different genetic mutation than olaparib. Niraparib is being studied in combination with other treatments, such as chemotherapy or targeted therapy.
Where the evidence stands
The evidence for ovarian cancer treatments ranges from approved treatments that are widely available to early-stage clinical trials that are still testing new approaches. Approved treatments, such as bevacizumab and olaparib, have been shown to be effective in clinical trials and are widely available to patients. Late-stage clinical trials, such as Phase 3 trials, are testing new combinations of existing treatments or new targeted therapies.
Early-stage clinical trials, such as Phase 1-2 trials, are testing new treatments that are still in the experimental stage. These trials are often small and may not have enough data to determine the effectiveness of the treatment. However, they can provide valuable information about the safety and potential effectiveness of new treatments.
What this means for people affected
The research landscape for ovarian cancer is complex and constantly evolving. While there are many effective treatments available, there is still a need for new approaches that can improve outcomes for patients. Researchers are actively studying new treatments and combinations of treatments, which may offer new hope for patients.
The field is moving quickly, with new clinical trials and studies being published regularly. However, it's essential to remember that each patient's situation is unique, and what works for one person may not work for another. Patients and their families should work closely with their healthcare team to determine the best course of treatment for their individual situation.